New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 31, 2012
12:53 EDTISRG, HNSNHansen Medical expands license agreement with Intuitive Surgical
Hansen Medical (HNSN) announced it has signed an updated license agreement with Intuitive Surgical (ISRG). Under the terms of the updated agreement, Intuitive Surgical's existing co-exclusive rights to Hansen Medical's patent portfolio to certain non-vascular approaches have been extended to include patents filed by Hansen Medical subsequent to the original 2005 agreement up to and including the period three years subsequent to this update. Hansen Medical retains the right to use its intellectual property for all clinical applications. This agreement is an update to the co-exclusive license agreement signed by the companies in 2005. Intuitive Surgical will pay Hansen Medical a $20Mup front license fee and will purchase 5,291,005 shares of Hansen Medical common stock for $10M through a private placement transaction. The shares were priced at $1.89, which represents a 5% premium to the trailing 10-day average of Hansen Medical's closing bid price on the Nasdaq Capital Market on October 26.
News For HNSN;ISRG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 15, 2015
10:29 EDTISRGAmerican Urological Association to hold an annual meeting
Subscribe for More Information
May 13, 2015
07:31 EDTHNSNHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
10:01 EDTISRGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:34 EDTISRGIntuitive Surgical initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Matt O'Brien started shares of Intuitive Surgical with a Neutral rating and $505 price target. O'Brien calls the stock "simply too expensive" relative to expected sales and earnings, but admits Intuitive's robotic surgical technology will likely dominate the market in the coming years. Further, the analyst thinks the company's da Vinci Prostatectomy and da Vinci Hysterectomy procedures could contract amid new diagnostic tests and insurance pushback. The stock closed yesterday up $2.05 to $496.37.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use